Compare Freeport-McMoRan Inc (FCX) vs Pfizer Inc (PFE) Price & Performance

Freeport-McMoRan (FCX) trades at $71.87, down 0.97% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected shortly. FCX maintains solid profitability with 11.38% net margin and 15.37% ROE, supported by robust operational cash flow of $5.61 billion in 2025. Recent news highlights copper's strategic importance for AI infrastructure, positioning FCX to benefit from long-term demand trends.

FCX presents a compelling opportunity with analyst consensus at Buy (61%) and $73.27 price target, offering 2% upside. The company's expansion projects and copper's AI-driven demand create growth potential, though rising production costs and ongoing legal investigation pose risks. Institutional sentiment remains positive given FCX's market leadership and favorable commodity outlook.

Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.

Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.